EXINI: Benefits using BSI highlighted at the annual Japanese Urological Association’s meeting in Kobe, April 24-27, 2014

| Source: EXINI Diagnostics AB

Lund, Sweden, 2014-05-08 08:48 CEST (GLOBE NEWSWIRE) --  


Arranged by Fujifilm RI Pharma and with significant EXINI representation, the symposium on April 25, focused on Bone Scan Index (BSI) as a quantitative assessment tool in relation to bone metastases from urologic cancer.

Distinguished Professors Nonomura Norio from Osaka University, and Kamai Takao from Dokkyo Medical University chaired the symposium. International BSI-authority, Dr. Michael Morris from Memorial Sloan Kettering Cancer Centre in New York, was invited to comment on the experiences and results presented by the following five keynote speakers:

Dr. Uemura Motohide, Osaka University
Outline of the bone metastases assessment by BONENAVI

Dr. Nozawa Masahiro, Kinki University
Assessment of the bone metastases with the bone metabolism marker

Dr. Ito Akito, Iwate Medical University
Utility and the future prospects of BONENAVI in renal carcinoma bone metastases

Dr. Mizokami Atsushi, Kanazawa University
Review prostate cancer bone metastases through BONENAVI

Dr. Shinohara Nobuo, Hokkaido University
Comparison between bone scan and other image assessment

”I am impressed by the outcome and by the attending authorities at this symposium. Fujifilm RI Pharma manages to draw attention to the medical benefits of extracting BSI-value from BONENAVI. This JUA-hosted symposium serves as a good example on how we can spread the knowledge on BSI’s importance as an Imaging Biomarker world wide, in relation to both prostatic- and breast cancer.” comments CEO Magnus Aurell.


For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com


About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its  own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.

         EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
         Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com